Abstract:Background and aim Treatment strategy of hepatocellular carcinoma (HCC) is a complex decision-making process that should consider several variables in clinical practice. Recently, a “multiparametric therapeutic approach” has been proposed (Vitale A, Cabibbo G et al Lancet Oncol 2023). In this approach, the feasibility of all treatments is evaluated systematically in a hierarchical order, to match each patient with the optimal therapy. The aim of the study is to validate the reliability of the new multi-parametric decisional framework (MPDF) and the impact of the different variables included in the framework on the final treatment decision in clinical practice. Methods This is a prospective ongoing study with a first monocentric phase (A) and a second multicentric validation phase (B). Primary endpoints are: 1) adherence to MPDF for treatment allocation and 2) identification of the relative weight of variables involved in this multiparametric evaluation to predict treatment decision, while secondary endpoints are overall survival (OS) and radiological response after treatment. The study includes all consecutive patients with HCC managed in each center from September 1st, 2023. The disease is staged according to Barcelona Clinic Liver Cancer (BCLC) classification, while patient's characterization is conducted by Charlson Comorbidity Index (CCI), modified CCI (mCCI), Liver Frailty Index (LFI), Child-Pugh (CPT) and ALBI scores, MELD and skeletal muscle mass index (SMI) by CT-evaluation. Each patient is allocated to treatment according to MPDF, BCLC 2022 was used as benchmark of treatment allocation. Results As of November 1st, 2023, 48 patients were recruited into phase A of the study [median age 70 (52-87) years, 81% male, 37% HCV-Ab positive, 27% first diagnosis/treatment of HCC]. Thirteen (27%) patients were classified as BCLC 0, 17 (35%) as BCLC A, 6 (12.5%) as BCLC B, 6 (12.5%) as BCLC C and 6 (12.5%) as BCLC D. The median CCI was 8 (4-13), the median LFI was 4.15 (2.99-4.81) which corresponds to a pre-frail condition. Thirty-nine (81%) patients were in CPT class A, 7 (15%) in B and 2 (4%) in C, while 32 (67%) were classified ALBI grade 1 and 16 (33%) ALBI grade 2, and finally the median MELD score was 8.5 (6-22). Forty-four (92%) patients received treatment through a multidisciplinary team (MDT). According to the MPDF, 9 (19%) patients were allocated to liver transplant, 5 (10%) to laparoscopic surgical resection, 10 (21%) to microwave thermal ablation (MWTA), 7 (15%) to transarterial treatments (4 TACE and 3 TARE), 3 (6%) to other locoregional therapies (2 MWTA+TACE and 1 electrochemotherapy), 6 (13%) to systemic treatment and 5 (10%) to palliative care only. In 4 cases, the MDT decided for follow-up at 3 months and subsequent reassessment. The reason why each therapy was excluded for each patient is shown in Table 1. The treatment allocation was coherent to the BCLC 2022 treatment allocation system in the 69.2% for BCLC 0, 82.4% for BCLC A, 83.3% for BCLC B, 66.7% for BCLC C and 100% for BCLC D. Conclusions Preliminary data of our ongoing prospective study suggest that personalized approach for HCC treatment by MPDF is feasible in clinical practice and might help ensuring a customized approach in a standardized framework. Updated data will be presented at the meeting.

Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania

Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina

Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage

Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations

Compliance to the American Association for the Study of Liver Diseases (AASLD) guidelines and its impact on overall survival in patients with hepatocellular carcinoma.

Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias

Improved handling of BCLC 2022 update in the management of hepatocellular carcinoma in clinical practice

Epidemiology, therapy and outcome of hepatocellular carcinoma between 2010 and 2019 in Piedmont, Italy

Impact of guideline adherence on the prognosis of Barcelona clinic liver cancer stage B hepatocellular carcinoma

Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy

The Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives

Characteristics and management of hepatocellular carcinoma (HCC) in Sicily: first results of the HCC Sicily Multidisciplinary Network

Comparative analysis of subclassification models in patients with intermediate stage hepatocellular carcinoma (BCLC B) receiving systemic therapy

Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma

Palliative care in patients with hepatocellular carcinoma: Results from a survey among hepatologists and palliative care physicians

Current management of hepatobiliary malignancies between centers with or without a liver transplant program: A multi-society national survey

[Hepatocellular carcinoma in a high-complexity public center in Argentina: epidemiological characteristics and therapeutic outcomes]

Treatment of hepatocellular carcinoma according to multiparametric therapeutic hierarchy approach: a prospective multicenter validation study

Clinical characteristics, therapeutic approach, and outcomes in patients with hepatocellular carcinoma at a third-level hospital.

Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma